Compare GIB & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIB | RDY |
|---|---|---|
| Founded | 1976 | 1984 |
| Country | Canada | India |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 11.8B |
| IPO Year | 1999 | 2001 |
| Metric | GIB | RDY |
|---|---|---|
| Price | $66.43 | $11.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $112.00 | $16.90 |
| AVG Volume (30 Days) | 393.1K | ★ 3.1M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.70% | 0.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.33 | $7.72 |
| Revenue Next Year | $2.96 | $3.50 |
| P/E Ratio | ★ $13.59 | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $59.63 | $11.36 |
| 52 Week High | $103.04 | $15.67 |
| Indicator | GIB | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 32.74 |
| Support Level | $60.78 | N/A |
| Resistance Level | $69.13 | $13.96 |
| Average True Range (ATR) | 1.70 | 0.39 |
| MACD | -0.06 | -0.21 |
| Stochastic Oscillator | 66.37 | 15.77 |
CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company is one of the major IT suppliers to different levels of government around the world. It offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services to governments and the private sector. With offices in over 40 countries, CGI follows a balanced global delivery model with most consultants in client proximity.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.